ImmunityBio, Inc. (IBRX)
Summary
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy
ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX's pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no immediate financial risks.
ImmunityBio: A Long-Term Bull Case Worth Watching
ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation.
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ImmunityBio, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 2 | $5.28 | $15.32 | $10.04 | 190.15% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,311 | $2,595.78 | $9,937.38 | $7,341.6 | 282.83% |
| BG Bart Gancher Intech Investment Management LLC | 80,988 | $222,003.93 | $613,889.04 | $391,885.11 | 176.52% |
| YA Yinka Akinsola Blue Trust Inc. | 772 | $5,921.24 | $5,874.92 | -$46.32 | -0.78% |
 Jeff Ameen Spire Wealth Management | 499 | $1,935.12 | $3,932.12 | $1,997 | 103.2% |
ImmunityBio, Inc. (IBRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ImmunityBio, Inc. ever had a stock split?
ImmunityBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard Gerald Adcock CEO | NASDAQ (NGS) Exchange | 45256X103 CUSIP |
| US Country | 671 Employees | - Last Dividend | - Last Split | 28 Jul 2015 IPO Date |
Overview
ImmunityBio, Inc. is a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of next-generation immuno- and cellular therapies. These therapies target cancer and infectious diseases, with operations spanning the United States and Europe. The company leverages its expertise to offer cutting-edge immunotherapy and cell therapy platforms aimed at enhancing patient outcomes. Through strategic collaboration agreements and licensing arrangements with various entities, including the National Cancer Institute and Amyris, Inc., ImmunityBio is working towards advancing its promising pipeline of therapies. The company is headquartered in San Diego, California, reflecting its strong presence in one of the world’s leading biotechnology hubs.
Products and Services
- Anktiva (N-803)
- Immunotherapy and Cell Therapy Platforms
- Collaborations and Licensing Agreements
An IL-15 superagonist antibody-cytokine fusion protein, Anktiva (N-803), represents ImmunityBio’s lead biologic commercial product candidate. It is designed for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without Ta or T1 disease. This highlights ImmunityBio’s focus on addressing hard-to-treat cancers through innovative biologic treatments.
ImmunityBio’s platforms encompass a variety of immunotherapy and cell therapy solutions aimed at fighting against cancer and infectious diseases. This includes antibody cytokine fusion proteins like N-803, sophisticated vaccine delivery technologies, and natural killer cell therapies. Through these platforms, the company is able to target a broad spectrum of liquid and solid tumors, as well as other severe diseases, demonstrating its versatility and innovation in the biotechnological field.
The company’s collaborative efforts and licensing agreements with institutions such as the National Cancer Institute, LadRx Corporation, GlobeImmune, Inc., and others play a critical role in bolstering its research and development activities. These partnerships facilitate the harnessing of external expertise and technologies, thereby enriching ImmunityBio’s product pipeline and accelerating the pace of innovation in treatments for cancer and infectious diseases.
